首页 | 官方网站   微博 | 高级检索  
     


Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors
Authors:Suhendan Ekmekcioglu PhD  Gerald S Falchook MD  Aung Naing MD  FACP  Jennifer J Wheler MD  Siqing Fu MD  PhD  Stacy L Moulder MD  Sarina Piha‐Paul MD  Apostolia M Tsimberidou MD  YueJin Wen MD  PhD  Kirk S Culotta PharmD  Kenna Anderes MD  Darren W Davis PhD  Wen Liu MD  Goldy C George PhD  Luis H Camacho MD  Susan Percy Ivy MD  Razelle Kurzrock MD
Affiliation:1. Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas;2. Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, Texas;3. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas;4. Apocell Molecular Profiling and Diagnostics, Houston, Texas;5. Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland;6. Division of Hematology and Oncology, Moores Cancer Center, University of California at San Diego, San Diego, California
Abstract:
Keywords:angiogenesis  phase 1  bevacizumab  cediranib
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号